Physician profile
David C Jacobs
NPI 1740372531
$2,532.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,135 · 2020: $397.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $918.35 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $498.77 | 2019-2020 | |
| Allergan, INC. | $311.02 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $289.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $250.79 | 2019 | |
| Neurocrine Biosciences, INC. | $120.19 | 2019 | |
| Lundbeck LLC | $58.47 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.43 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $21.26 | 2019 | |
| Bausch Health US, LLC | $17.80 | 2019 | |
| Alkermes, INC. | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.